Influence of betacyclodextrin on the release of poorly soluble drugs from inert and hydrophilic heterogeneous polymeric matrices. 2001

M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
lstituto di Chimica Farmaceutica e Tossicologica, Università di Milano, Italy. maria.sangalli@unimi.it

The release behavior of poorly soluble drugs (naproxen and ketoprofen) from inert (acrylic resins) and hydrophilic swellable (high-viscosity hydroxypropylmethylcellulose) tableted matrices containing betacyclodextrin (betaCD) was investigated. The results demonstrated that, in both cases, betaCD can enhance the rate of drug release. Matrices obtained from formulations in which lactose replaced betaCD were also evaluated. BetaCD in inert matrices causes a dramatic increase in the rate of drug release, higher than that promoted by lactose which merely acts as a channelling agent. This result suggests that possible in situ formation of the drug-betaCD complex. which causes an improvement in apparent drug solubility, could have a greater influence on the rate of drug release than the possible increase of water uptake by a soluble filler. Indeed, if the opposite were true, lactose would be more effective in increasing the rate of drug release than betaCD, because of its greater solubility in water. On the contrary, in the case of hydrophilic matrices, lactose proves to be much more effective in promoting drug release than betaCD. It seems that, while the bulky interaction compound can freely diffuse through water-filled pores of inert systems, its diffusion through swollen macromolecular chains of hydrophilic matrices may be hindered. This hypothesis was supported by data obtained from binary (drug/polymer) and ternary (drug/polymer/betaCD) hydrophilic matrices using a betaCD-containing dissolution media.

UI MeSH Term Description Entries
D007660 Ketoprofen An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis. Benzoylhydratropic Acid,19,583 RP,2-(3-Benzoylphenyl)propionic Acid,Alrheumat,Alrheumum,Orudis,Profenid,RP-19583,RP 19583,RP, 19,583,RP19583
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009288 Naproxen An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. Aleve,Anaprox,Methoxypropiocin,Naprosin,Naprosyn,Naproxen Sodium,Proxen,Sodium Naproxenate,Synflex,Naproxenate, Sodium,Sodium, Naproxen
D003505 Cyclodextrins A homologous group of cyclic GLUCANS consisting of alpha-1,4 bound glucose units obtained by the action of cyclodextrin glucanotransferase on starch or similar substrates. The enzyme is produced by certain species of Bacillus. Cyclodextrins form inclusion complexes with a wide variety of substances. Cycloamylose,Cyclodextrin,Cyclodextrin Derivatives,Cyclomaltooligosaccharides,Derivatives, Cyclodextrin
D004337 Drug Carriers Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers. Drug Carrier
D001672 Biocompatible Materials Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function. Biomaterials,Bioartificial Materials,Hemocompatible Materials,Bioartificial Material,Biocompatible Material,Biomaterial,Hemocompatible Material,Material, Bioartificial,Material, Biocompatible,Material, Hemocompatible
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D047392 beta-Cyclodextrins Cyclic GLUCANS consisting of seven (7) glucopyranose units linked by 1,4-glycosidic bonds. beta Cyclodextrins

Related Publications

M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
October 1974, Arzneimittel-Forschung,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
August 2018, AAPS PharmSciTech,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
January 1978, Pharmaceutica acta Helvetiae,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
April 1974, Die Pharmazie,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
May 2003, Die Pharmazie,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
August 2011, Journal of controlled release : official journal of the Controlled Release Society,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
September 2004, Journal of pharmaceutical sciences,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
January 2007, Molecular pharmaceutics,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
October 2004, Cellular and molecular life sciences : CMLS,
M E Sangalli, and L Zema, and A Maroni, and A Foppoli, and F Giordano, and A Gazzaniga
October 1990, Journal of pharmaceutical sciences,
Copied contents to your clipboard!